Skip to content
Wenlo
Sign in
← Markets

CG Oncology Inc.

Leonard E Post (Director) sells CGON shares

4CGONFiled Oct 19, 2026, 12:30 PM ET· Period Oct 15, 2026

About this filing

CG Oncology Inc. (CGON) filed Form 4 (insider transaction) with the SEC on Oct 19, 2026. Form 4 reports a company insider’s trades in the company’s shares.

Key facts

Insider
Leonard E Post · Director

Rule 10b5-1 plan · adopted Mar 5, 2026

DateTransactionSharesPriceValueHeld afterOwnership
Oct 15, 2026M · exercise or conversion of a derivative+1,000$0.60$600.001,000Direct
Oct 15, 2026S · open-market saleFootnotes F1, F2−500$61.65$30,825.00500Direct
Oct 15, 2026S · open-market saleFootnotes F1, F3−500$62.48$31,240.000Direct
Oct 15, 2026M · exercise or conversion of a derivativeDirector Stock Option (right to buy)Footnotes F4−1,000$0.00$0.00102,077Direct
Footnotes
  1. F1 The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
  2. F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.16 to $62.06 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.27 to $62.60 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  4. F4 Fully vested

More CGON filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.